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ABSTRACT 
 
The Novel Bacterial Topoisomerase Inhibitor class is an investigational type of 
antibacterial inhibitor of DNA gyrase and topoisomerase IV that do not have cross-
resistance with the quinolones. Here, we report the evaluation of the in vitro 
properties of a new series of this type of small molecules. Exemplar compounds 
selectively and potently inhibited the catalytic activities of Escherichia coli DNA 
gyrase and topoisomerase IV but did not block the DNA breakage-reunion step. 
Compounds showed broad-spectrum inhibitory activity against a wide range of Gram-
positive and Gram-negative pathogens, including biodefence microorganisms, and 
Mycobacterium tuberculosis. No cross-resistance with quinolone-resistant 
Staphylococcus aureus and E. coli isolates was observed. Measured MIC90 values 
were 4 and 8 µg/mL against a panel of contemporary multidrug-resistant isolates of 
Acinetobacter baumannii and E. coli. In addition, representative compounds exhibited 
greater antibacterial potency than the quinolones against obligate anaerobic species. 
Spontaneous mutation rates were low, with frequencies-of-resistance typically <10-8 
against E. coli and A. baumannii at concentrations equivalent to four-fold the MIC. 
Compound-resistant E. coli mutants isolated following serial passage were 
characterised by whole-genome sequencing and carried a single Arg38Leu amino 
acid substitution in the GyrA subunit of DNA gyrase. Preliminary in vitro safety data 
indicate that the series shows a promising therapeutic index and potential for low 
hERG inhibition (IC50 >100 µM). In summary, the FRPSRXQGV¶ distinct mechanism-of-
action relative to the fluoroquinolones, whole-cell potency, low potential for 
resistance development and favorable in vitro safety profile warrant their continued 
investigation as potential broad-spectrum antibacterial agents. 
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INTRODUCTION 
 
Bacterial infections are becoming increasingly untreatable owing to the rapid emergence of 
multidrug-resistance as well as the limited number of novel antibacterial agents in clinical 
development (1, 2, 3). The United States Centers for Disease Control and Prevention (CDC) 
recently identified 15 antibiotic-resistant microorganisms as posing a threat to human health 
classified as µ8UJHQW¶ or µ6HULRXV¶ (4). Prominent amongst this set are antibiotic-resistant 
strains of the µESKAPE¶ group of species (1), such as carbapenem-resistant 
Enterobacteriaceae (CRE), multi-drug-resistant (MDR) Acinetobacter, MDR Pseudomonas 
aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
Enterococcus (VRE). Also in the list are the Gram-positive anaerobe Clostridium difficile, 
drug-resistant Neisseria gonorrhoeae and drug-resistant tuberculosis. 
 
The urgent need to discover and develop new antibacterial agents to counter the threat of 
drug-resistant infections is widely recognised. Research efforts over the past few years have 
focused on the development of novel classes of antibacterials with a dual-targeting 
mechanism-of-action distinct from currently-used antibiotics, with the twin objectives of 
avoiding cross-resistance and reducing the emergence of de novo resistance. The essential 
bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV, are well-
validated drug targets for antibiotic pharmacology as evidenced by the fluoroquinolone and 
aminocoumarin classes of antibiotics (5, 6, 7, 8). These enzymes are responsible for 
introducing negative supercoils into DNA and for the decatenation of DNA. The high degree 
of sequence similarity between DNA gyrase and topoisomerase IV offers the prospect of 
multi-targeting with a single pharmacophore (9, 10). Despite the now widespread resistance 
to the quinolones, the type II topoisomerases continue to provide opportunities for 
antibacterial discovery based on exploiting novel binding interactions between new chemical 
ligands and the target enzymes in order to bypass mutations associated with quinolone 
resistance. Selected examples of this strategy are the 2-aminoquinazolinedione (11), the 
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isothiazoloquinolone (12), the spiropyrimidinetrione (13) and the novel tricyclic 
topoisomerase inhibitor (NTTI) (14) classes.    
 
One emerging class of non-quinolone inhibitors of DNA gyrase and topoisomerase IV is the 
Novel Bacterial Topoisomerase Inhibitor (NBTI) type. NBTI molecules bind to a site which is 
distinct from, but adjacent to, the catalytic centre of DNA gyrase/topoisomerase IV that is 
occupied by the quinolones (15). Consequently, NBTI compounds retain potency against 
quinolone-resistant isolates. Structurally, NBTI molecules comprise a northern head group 
that interacts with the DNA, a central linker portion, and a southern group that binds to the 
enzymes. A number of advanced NBTI molecules have been described in the literature, 
including NXL101 (16), AZD9742 (17), NBTI 5463 (18) and gepotidacin (19), which recently 
successfully completed phase II human clinical evaluation for the treatment of 
uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae (NCT02294682). The 
NBTI pharmacophore, however, has been associated with cardiovascular and other safety 
liabilities (17, 20, 21, 22, 23). A key aim in the development of NBTIs, therefore, is achieving 
broad antibacterial potency, including against challenging Gram-negative pathogens, whilst 
maintaining satisfactory safety margins.   
 
Towards this goal, Redx Pharma recently disclosed a new series of NBTI type compounds 
characterised by a novel tricyclic northern head group as described in International Patent 
WO 2016/024096 (24). The chemical structures of six selected compounds from this series 
are displayed in Figure 1. The purpose of this present study was to undertake a detailed in 
vitro biological evaluation of exemplar compounds from the series. Specifically, their ability 
to inhibit DNA gyrase and topoisomerase IV activities; their whole-cell potency against 
panels of wild-type and quinolone-resistant bacteria, including clinically-important anaerobes 
and biodefence organisms; and their in vitro safety profiles were assessed and are reported.  
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MATERIALS AND METHODS 
 
Reagents and media. Proprietary compounds were prepared at Redx Pharma as described 
in International Patent Application WO 2016/024096. Reference antibiotics were purchased 
from Sigma Aldrich (Dorset, UK). Bacteriological media were purchased from Oxoid Ltd 
(Basingstoke, UK).  
 
Bacterial strains. The bacteria used in this study were obtained from the American Type 
Culture Collection (ATCC, Middlesex, United Kingdom), the Network on Antibacterial 
Resistance in Staphylococcus aureus (Manassas, Virginia) or the Coli Genetic Stock Center 
(New Haven, Connecticut). Escherichia coli strains MG1655 WT, MG1655 S83L and 
MG1655 D87G were provided by Professor Tony Maxwell (John Innes Centre, Norwich, 
United Kingdom). E. coli ECCPX1-SP25 was selected and characterised at Redx Pharma by 
the serial passage of E. coli ATCC 25922 in the presence of ciprofloxacin as described in 
International Patent WO 2016/024098 (25). 
 
DNA supercoiling, decatenation and cleavage complex. DNA supercoiling, decatenation 
and cleavage complex assays were all performed by Inspiralis Ltd (Norwich, United 
Kingdom) using a gel-based assay format. Briefly, one unit of E. coli DNA gyrase (WT or 
Arg38Leu mutant) was incubated with 0.5 µg of relaxed pBR322, and one unit of 
topoisomerase IV (WT) or human topoisomerase II was incubated with 200 ng kDNA, all in a 
reaction volume of 30 µL at 37 °C for 30 min in the presence of a series of concentrations of 
the test compound. Supercoiling reactions were conducted under the following conditions: 
35 mM Tris.HCl (pH 7.5), 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 1.8 mM Spermidine, 1 mM 
ATP, 6.5 % (w/v) glycerol and 0.1 mg/ml BSA. E. coli topoisomerase IV decatenation 
reactions were conducted under the following conditions: 50 mM HEPES-KOH (pH 7.6), 100 
mM potassium glutamate, 10 mM magnesium acetate, 10 mM dithiothreitol, 1 mM ATP and 
50 ȝJPO BSA. Inhibition of human topoisomerase II decatenation activity was assessed as 
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described previously (14). Reactions were stopped using 30 ȝ/ chloroform/iso-amyl alcohol 
(26:1) and 20 ȝL Stop Dye (40 % sucrose, 100 mM Tris.HCl [pH 7.5], 1 mM EDTA, 0.5 
ȝJP/ bromophenol blue). Topoisomers were visualised by ethidium bromide staining, 
resolved and quantified by gel electrophoresis and the band intensities analysed by gel 
documentation equipment (Syngene, Cambridge, UK) and quantified using Syngene Gene 
Tools software. Raw data were converted to a percentage of the inhibitor-free control and 
were analysed using SigmaPlot Version 12.5. Non-linear regression was used to calculate 
the half-inhibitory concentrations (IC50). The human topoisomerase II inhibitor, etoposide, 
was used as a positive control for inhibition for this assay. For cleavage complex assays, 
compounds were tested at 100 ȝ0 in a final DMSO concentration of 1 % (v/v). E. coli DNA 
gyrase (one unit) was incubated with 0.5 ȝJ of supercoiled pBR322 DNA at 37 °C for 30 min. 
Reactions were performed in a volume of 30 µL using the following conditions: 35 mM 
Tris.HCl (pH 7.5), 24 mM KCl, 4 mM MgCl2, 2 mM DTT, 1.8 mM Spermidine, 6.5% (w/v) 
glycerol and 0.1 mg/mL BSA. Following this, reactions were incubated for 30 min with 0.2 % 
SDS and 0.5 ȝJȝ/ proteinase K. Reactions were stopped in the same manner as for the 
supercoiling and decatenation assays. Topoisomers and cleavage products were visualised 
by gel electrophoresis. Cleavage products were expressed as a percentage of the fully 
supercoiled inhibitor-free control as described for the supercoiling and decatenation assays. 
 
Antibacterial susceptibility testing. MICs were determined by the broth microdilution 
procedure according to the guidelines of the Clinical and Laboratory Standards Institute 
M07-A10 (26). The broth microdilution method involved a two-fold serial dilution of 
compounds in 96-well microtitre plates, giving a typical final concentration range of 0.25-128 
µg/mL and a maximum final concentration of 1 % DMSO. Strains were grown in cation-
adjusted Müller-Hinton broth (CA-MHB) or agar (CA-MHA) with or without 5 % lysed horse 
blood at 37 °C in an ambient atmosphere, in haemophilus testing medium broth at 37 °C in 
an ambient atmosphere, or in gonococcal broth or agar supplemented with Vitox at 37 °C in 
an atmosphere containing 5 % CO2. The MIC was determined as the lowest concentration of 
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compound that inhibits visible growth following a 16-24 h incubation period. For 
Mycobacterium tuberculosis, a fluorescent reporter strain of H37Rv was used and the MIC 
was determined by measuring the optical density (OD590) or fluorescence (Ex 560 nm/Em 
590 nm) after five days of growth in 7H9 broth with 10 % v/v OADC supplement and 0.05 % 
w/v Tween 80 in the presence of test compound with a final DMSO concentration of 2 %. 
MIC90 determination was performed at IHMA Europe Sàrl (Epalinges, Switzerland) with a 
selection of clinical isolates collected between 2012 and 2014. Bacteria were obtained from 
a variety of infection types and geographical locations including at least 25 % highly drug-
resistant isolates (resistant to at least seven out of amikacin, aztreonam, cefepime, 
ceftazidime, ceftriaxone, colistin, gentamicin, imipenem/meropenem, levofloxacin, 
piperacillin-tazobactam and tetracycline) and with a selection of 10 different species of 
anaerobes, including 113 isolates collected in 2015 from diverse geographical origins. MICs 
were performed using frozen 96-well antibacterial panels prepared by broth microdilution in 
line with the guidelines of the Clinical and Laboratory Standards Institute M11-A8 (27), giving 
a final compound concentration range of 0.004 to 64 µg/mL. The inoculum size was 5 × 105 
CFU/mL and 5 × 107 CFU/mL for the aerobic and anaerobic strains, respectively. The testing 
plates for anaerobes were incubated for 48 h at 35 °C with 5 % CO2 in an anaerobic cabinet 
(Whitley A35 anaerobic workstation, Don Whitley Scientific). MICs were read visually and 
values were reported as MIC90 for inhibition of 90 % of the isolates. MIC testing of Bacillus 
anthracis, Burkholderia mallei, Burkholderia pseudomallei, Francisella tularensis and 
Yersinia pestis was undertaken by Southern Research (Birmingham, Alabama). Assay 
medium was CA-MHB (supplemented with 2 % IsoVitalex in the case of F. tularensis). 
Cultures were incubated in the presence of compound for up to 24 h, up to 38 h (F. 
tularensis) or 24-48 h (Y. pestis). 
 
Time-kill. The rate of bactericidal activity of compounds was determined against A. 
baumannii NCTC 13420 at 4 × and 8 × MIC according to guidelines of the Clinical and 
Laboratory Standards Institute M26-A (28). A. baumannii was cultured overnight at 37°C, 
8 
diluted in fresh CA-MHB and grown to exponential phase (OD600nm = 0.3). Cultures were then 
adjusted to 0.5 McFarland units (1-2 × 108 CFU/mL) before addition of compound to give a 
final concentration of 4 × or 8 × MIC. Samples were taken at 0, 0.5, 1, 3, 6 and 24 h, serial 
diluted and plated onto MHA, followed by overnight incubation at 37 °C. The following day, 
colonies were enumerated to determine CFU/mL.  
 
Frequency of resistance. Overnight cultures of bacteria were grown from single colonies in 
CA-MHB. The following day, samples of the neat cultures were spread onto CA-MHB 
containing compound at the concentrations indicated. To determine the number of viable 
cells in the inoculum, samples of the overnight cultures were serially-diluted in phosphate-
buffered saline (PBS) and plated on compound-free CA-MHA. Plates were incubated for up 
to 48 h and the colonies were enumerated. The spontaneous frequency of resistance (FoR) 
was calculated by dividing the number of resistant colonies (CFU/mL) by the total number of 
viable cells (CFU/mL). 
 
Selection of resistant mutants by serial passage. Resistant mutants were selected by 
serial passage carried out using the broth microdilution method. Following MIC 
determination the culture representing 0.25 × MIC was used to inoculate the subsequent 
passage until the desired level of resistance was achieved. At this point, clones were 
isolated and the MIC confirmed as described above. 
 
Whole-genome sequencing. Genomic DNA (gDNA) was extracted from the resistant 
strains using the PurElute Bacterial Genomic Kit (Edge BioSystems, Gaithersburg, 
Maryland). The gDNA was purified according to the PDQXIDFWXUHU¶V instructions. Purified 
gDNA was used to create whole genome libraries using NEBNext Ultra kit and 150 bp paired 
end read sequence data were produced using an Illumina HiSeq 3000. Read data were 
stored as FASTQ files and then adaptor sequences were removed using cutadapt software 
(Version 1.8). Data for the wild-type strain was used to construct a reference genome 
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sequence using the CLCBio genome assembler (Version 8.0.1). Sequence data for each 
sample, including the progenitor strain, were aligned to the published E. coli ATCC 25922 
genome using BWA (Version 0.7.12); aligned data and were sorted using Samtools6 
(Version 1.2). Variants were identified using VarScan (Version 2.3.7) using the E. coli ATCC 
25922 assembled genome as the reference sequence. The resulting data provided coverage 
of >100 reads across the genome. Single nucleotide polymorphisms (SNPs), insertions and 
deletions were identified that were prevalent in  % of the reads compared with the 
progenitor strain. 
 
Cytotoxicity testing. HepG2 cells (ATCC HB-8065) were seeded at a density of 20,000 
cells per well and incubated for 24 h at 37 °C in an atmosphere of 5 % CO2. Cells were then 
exposed to a doubling dilution series of the test compound. After 24 h of incubation, the 
viability of the cells was determined using CellTiter-Glo® (Promega, WI, USA), according to 
the PDQXIDFWXUHU¶V instructions. Each experiment was carried out in duplicate and the results 
reported as the average concentration of test compound inhibiting 50 % of cell viability 
(IC50). 
 
hERG Inhibition. Inhibition of the human Ether-a-go-go Related Gene (hERG) cardiac 
potassium (K+) ion channel was determined in a transfected Chinese Hamster Ovary K1 
(CHO) cell line using IonWorks patch clamp electrophysiology (29). 
 
LogD measurements. Partitioning of compounds between 1-octanol and 0.1 M phosphate 
buffer (pH 7.4) was measured using the shake-flask method (30).  
 
RESULTS 
 
Inhibition of target activity in vitro. The five compounds tested potently inhibited both E. 
coli DNA gyrase and topoisomerase IV enzymes, consistent with a dual-targeting 
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mechanism-of-action (Table 1). Ciprofloxacin was selected as a representative quinolone 
and tested in parallel for comparison. REDX05777, REDX06181, REDX06213, REDX07623 
and REDX07638 produced a range of IC50 values comparable with ciprofloxacin in the 
supercoiling assay, while all five compounds showed approximately 10-fold lower IC50 
values than ciprofloxacin in the decatenation assay. Stabilisation of the DNA gyrase 
cleavage complex was observed in the presence of ciprofloxacin (35 % at 100 µM), while all 
Redx compounds showed little or no stabilisation of this complex at the same concentration. 
Taken together, these results indicate that the Redx compounds potentially have a more 
balanced dual targeting activity when compared to ciprofloxacin and a distinct mechanism-
of-action. Similar to ciprofloxacin, Redx compounds showed a high degree of selectivity for 
the bacterial enzymes over the homologous mammalian enzyme, human topoisomerase II, 
with approximately two orders of magnitude difference in the measured IC50 values (Table 1).   
 
Bacterial susceptibility profile. Bacterial susceptibility profiling of the NBTI compounds 
shows that the series has broad-spectrum activity against Gram-negative and Gram-positive 
pathogens tested, including those of the µESKAPE¶ group of microorganisms (Table 2). 
Compounds from the series were generally more potent against the Gram-positive species. 
Compounds were active against fastidious Gram-negatives, such as Haemophilus 
influenzae and Neisseria gonorrhoeae, as well as non-fastidious Gram-negative species. Of 
the non-fastidious Gram-negatives, Redx compounds demonstrated more potent activity 
against Acinetobacter baumannii and E. coli in comparison to Enterobacter cloacae, 
Klebsiella pneumoniae and Pseudomonas aeruginosa. Representative compound 
REDX05777 also potently inhibited the whole-cell proliferation of Mycobacterium 
tuberculosis (Table 2). The exemplar compound REDX07638 was tested against a set of 
five biothreat microorganisms that included the aetiological agents of anthrax, Glanders, 
meliodosis, tularaemia and the plague (Table 3). REDX07638 inhibited all five Gram-positive 
and Gram-negative species, inhibiting Bacillus anthracis, Francisella tularensis and Yersinia 
pestis most potently. 
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Compounds retained potency against the E. coli strains, MG1655 S83L and MG1655 D87G, 
carrying the Ser83Leu and Asp87Gly mutations in the GyrA subunit of DNA gyrase that are 
associated with quinolone resistance. In all cases the MIC for the mutants was within one-
doubling-dilution either side of the MIC for the isogenic parent strain E. coli MG1655. By 
contrast, the MIC of ciprofloxacin increased 8-16-fold against the MG1655 S83L and 
MG1655 D87G strains compared to the isogenic parent (Table 2). E. coli ECCPX1-SP25 is a 
ciprofloxacin-resistant mutant derived from strain ATCC 25922. The MIC of ciprofloxacin 
against this strain is elevated 1024-fold relative to the parent strain. In comparison, the 
activity of Redx compounds against E. coli ECCPX1-SP25 was within 2-to-8-fold of strain 
ATCC 25922 (Table 2). Taken together, these results indicate a lack of cross-resistance of 
the NBTI series with the quinolone class of antibiotics.  
 
A selection of Redx compounds were tested against a panel of recent multidrug-resistant 
(MDR) and quinolone-resistant Gram-negative clinical isolates (Table 4). All three 
compounds tested showed antibacterial activity against E. coli with a MIC90 of 4 or 8 µg/mL. 
Similar activity was observed with REDX07623, REDX06213 and REDX06276 against A. 
baumannii with MIC90 of 4 or 8 µg/mL. The MIC90 values observed for these NBTI 
compounds against E. coli and A. baumannii were lower than those obtained for the 
fluoroquinolone antibiotic levofloxacin (16 µg/mL). REDX06276 was the most active 
compound from this series against the K. pneumoniae panel with a MIC90 of 16 µg/mL, 
comparable to levofloxacin. Activity against P. aeruginosa and E. cloacae was observed at 
32-to-64 µg/mL for all compounds tested, which was similar to the MIC90 values obtained for 
levofloxacin. 
 
Finally, compounds were tested for activity against species of clinically-significant obligate 
anaerobic Gram-positive and Gram-negative bacteria. Antibiotics of the quinolone class 
have generally shown poor-to-moderate in vitro antibacterial potency against anaerobic 
bacteria relative to other classes of antibiotics and compared with their potency against 
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aerobic bacteria (31, 32). Metronidazole and vancomycin were equally effective against a 
panel of recently-isolated anaerobes including the Gram-positive strains of P. harei, P. 
anaerobius and C. perfringens with MIC90 values lower or equal to 2 µg/mL (Table 5). 
Metronidazole, however, was not active against P. acnes while the Redx compounds 
maintained activity with MIC90 values of 0.5 and 4 µg/mL. Similar to ciprofloxacin, the tested 
compounds showed reduced activity against the Gram-positive strains of F. magna and P. 
micra with MIC90 values 16-64 µg/mL. Redx compounds showed activity at 2-to-16 µg/mL 
against the four Gram-negative bacterial species tested. Although metronidazole displayed 
lower MIC90 values (0.25-to-2 µg/mL), the NBTI compounds showed improved activity 
compared to ciprofloxacin and vancomycin.     
 
Time-kill. The rate of bactericidal activity was determined for REDX06213 and REDX07623 
against A. baumannii NCTC 13420 at 4 × and 8 × MIC. REDX06213 demonstrated 
bactericidal activity, showing a 3-log drop in CFU/mL at 2.6 and 2.8 h at 4 × and 8 × MIC, 
respectively (Figure 2). A 3-log reduction in CFUs was not achieved within 24 h with 
REDX07623 at 4 × MIC; however at 8 × MIC a 3-log drop in CFU/mL was observed at 0.97 
h (Figure 2). Regrowth was observed with REDX07623 at 4 × and 8 × MIC and with 
REDX06213 at 4 × MIC, but not at 8 × MIC. Regrowth at 24 h is not uncommon and has 
previously been reported for bactericidal antimicrobials such as ciprofloxacin against E. coli 
(33). However, this effect was not reported in a separate study with A. baumannii (34). 
 
Selection of resistant mutants. In order to assess the propensity for the development of de 
novo resistance to this class of NBTI compounds, the spontaneous frequency of resistance 
to REDX06213, REDX06276, REDX07623 and REDX07638 was determined with E. coli 
strain ATCC 25922. No mutants could be isolated at concentrations equivalent to 4 × MIC, 
yielding frequency-of-resistance ranging from <2.5 × 10-9 to <3.3 × 10-9. By comparison, the 
frequency-of-resistance to ciprofloxacin at 4 × MIC was 7.8 × 10-8 for E. coli ATCC 25922. 
To confirm that the observed mutation frequencies were not species-specific, frequencies-of-
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resistance values were also determined for REDX06213, REDX07623 and REDX07638 in 
A. baumannii strain NCTC 13420. Again, no mutants were isolated, yielding frequencies-of-
resistance between <6.7 × 10-8 and <7.4 × 10-8. 
 
Next, E. coli ATCC 25922 was used in serial passage experiments with REDX06276 as a 
representative compound from this NBTI series. Ciprofloxacin and delafloxacin were used as 
comparator antibiotics. The MIC of ciprofloxacin increased up to 64 µg/mL after 25 passages 
with resistance observed at passage 23 (MIC  4 µg/mL). The MIC of delafloxacin, however, 
remained within 2-fold of the original MIC (0.5 µg/mL) up to passage 24, after which it 
increased steadily to reach 16 µg/mL (32-fold increase) at passage 45. The MIC of 
REDX06276 followed a comparable trend to delafloxacin with an increase up to 32-fold (MIC 
64 µg/mL) at passage 45, at which stage the experiment was ended (Figure 3). Whole 
genome sequencing of the ciprofloxacin-resistant mutant from passage 25 (ECCPX1-SP25) 
revealed Ser83Leu and Asp87Gly mutations in the GyrA subunit and a Glu84Lys mutation in 
the ParC subunit. The delafloxacin-resistant mutant at passage 45 had target gene 
mutations corresponding to Ala119Glu and Ala179Val amino acid substitutions in the GyrA 
subunit. The REDX06276-resistant mutant from passage 45 carried a single Arg38Leu 
substitution in the GyrA subunit. In addition to target mutations, several off-target mutations 
were identified in all mutants (Table S1). Introduction of the single Arg38Leu mutation into E. 
coli DNA gyrase led to a modest increase in IC50 of 10 to 17 fold for all compounds, with the 
exception of REDX06213 (no significant change in activity) in the enzyme assay (Table 1). 
However, whole-cell MIC testing revealed a loss in potency of 64-256 fold (Table S2).  
 
In vitro safety profile. Mammalian cytotoxicity testing with the HepG2 cell line revealed IC50 
values that were higher than the corresponding MIC values observed with the ESKAPE 
pathogens by more than two orders of magnitude (Table 6). In vitro testing showed the 
series to have a range of hERG inhibitory activity, with REDX07623 having an IC50 of 8.2 
µM, whilst REDX6181 demonstrated reduced hERG inhibition with an IC50 >100 µM. A trend 
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between logD and hERG activity was found with this series. Compounds with a lower logD 
appeared to have reduced hERG inhibition (Table 6).   
 
DISCUSSION 
 
In recent years the growing threat of drug-resistant bacterial infections, combined with the 
lack of new antibiotics with a novel mechanism-of-action, has caused global concern. 
Resistance of Gram-negative species to first line and last resort antibiotics has been 
reported worldwide and can lead to untreatable infections and increased mortality (35). To 
address this unmet medical need, this study describes the in vitro assessment of a NBTI 
series with dual-targeting activity against bacterial DNA gyrase and topoisomerase IV and 
with a different mechanism-of-action to clinically-used fluoroquinolones. Redx compounds 
demonstrated potent, balanced inhibitory activity versus the two topoisomerase enzymes, 
with IC50 values ranging from 0.21 to 1.66 µM with E. coli DNA gyrase and between 0.10 and 
1.17 µM against E. coli topoisomerase IV (Table 1). Inhibitory activity was more balanced 
than ciprofloxacin, which had IC50 values of 0.77 and 10.20 µM against E. coli gyrase and 
topoisomerase IV, respectively. This is in agreement with data recorded in the literature, 
which shows ciprofloxacin to have a preference for DNA gyrase in E. coli and topoisomerase 
IV in S. aureus (36). Importantly, selectivity over human topoisomerase II was found with 
bacterial enzymes showing an approximate 100-fold increase in sensitivity to Redx 
compounds. The formation of DNA cleaved complexes was limited with Redx compounds in 
comparison to the level observed with ciprofloxacin (Table 1). This indicates that the NBTI 
series described here has a different mechanism-of-action to ciprofloxacin, which stabilises 
double-stranded broken DNA strands, blocking re-ligation, the consequences of which are 
poisonous to the bacterial cell. Instead, the NBTIs described here interact with the 
topoisomerase and DNA prior to double strand breakage, which has been reported for other 
NBTI series (18). 
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Broad-spectrum antibacterial activity was found with this series against a panel of ESKAPE 
pathogens, the fastidious Gram-negative organisms H. influenzae and N. gonorrhoeae, as 
well as M. tuberculosis and important Gram-positive and Gram-negative biothreat pathogens 
(Table 2 and 3). Potency was maintained against FQR E. coli isolates with a single amino 
acid substitution in the GyrA subunit (Ser83Leu or Asp87Gly) with MICs within two-fold of 
the MIC for the isogenic parent strain. Additionally, compounds retained potency against the 
serial passage FQR mutant E. coli ECCPX1-SP25, with MICs increasing eight-fold or less, in 
comparison to ciprofloxacin which showed a 1024-fold increase in MIC. The retained 
potency of this series against FQR mutants supports the different mechanism-of-action to 
the fluoroquinolones indicated by the cleavage complex enzyme assay. Overall, a reduction 
in antibacterial activity was found when Redx compounds were tested against a larger panel 
of clinically-relevant strains (25 % MDR). Antibacterial activity was retained against A. 
baumannii and E. coli, with values of 4-8 µg/mL; however, a loss of potency was found 
against the other Gram-negative species, K. pneumoniae, E. cloacae and P. aeruginosa, 
with MIC90 values of 16-32 µg/mL. Activity of Redx compounds were equal or superior to 
levofloxacin and other fluoroquinolones reported in the literature (37); although the reduced 
activity against a wider panel of strains shows modifications to improve antibacterial potency 
will be essential during continued development. In addition to good activity against ESKAPE 
pathogens, compounds demonstrated antibacterial activity against a panel of anaerobic 
pathogens including Clostridium and Bacteroides species (Table 2 and 5). In Europe, C. 
difficile is estimated to cause 250,000 infections and 14,000 deaths per annum, showing 
resistance to a large number of antibiotics including the fluoroquinolones (38). Bacteroides 
species are part of the mammalian gut microbiota and can be opportunistic pathogens as 
well as a reservoir for resistance. They are also frequently resistant to a wide range of 
antibiotics, necessitating development of novel compounds that are effective against these 
species. 
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Rapid, bactericidal activity of the series was demonstrated with representative compounds, 
REDX06213 and REDX07623, against A. baumannii NCTC 13420, with both compounds 
causing a 3-log drop in CFU/mL at 2.6 h (4 × MIC) and 0.97 h (8 × MIC), respectively (Figure 
2). The rate of bactericidal activity was similar or superior to that for ciprofloxacin and other 
NBTIs reported in the literature (33, 39, 40). Interestingly, REDX06213 caused a similar rate 
of bactericidal activity at 4 × and 8 × MIC, indicating time-dependent rather than 
concentration-dependent killing.   
 
No mutants were raised against compounds tested at 4 × MIC with A. baumannii NCTC 
13420 and E. coli ATCC 25922. By contrast, a mutation rate of 4.76 x 10-8 was obtained with 
E. coli ATCC 25922 against ciprofloxacin at equivalent multiples of its MIC. These results 
indicate a low potential for resistance development to this series and support the balanced 
dual-targeting activity revealed by the supercoiling and decatenation assay data. 
Development of resistance to other NBTI series at 4 × MIC has been reported in the 
literature. Resistance rates of 5 × 10-8 were found with NBTI 5463 against P. aeruginosa 
PAO1, although sequencing showed no target gene mutations (18). Second- and third-step 
mutants had Asp82Glu and Asp82Glu plus Asp87Tyr point mutations in GyrA, respectively 
(41). These mutants showed no cross-resistance to the fluoroquinolones consistent with a 
differential binding mechanism between the NBTI and fluoroquinolone classes of 
topoisomerase inhibitors. Although no mutants were raised during the spontaneous 
frequency-of-resistance experiments against the compounds described here, whole genome 
sequencing of the E. coli REDX06276 serial passage mutant revealed a single Arg38Leu 
substitution in the GyrA subunit. This mutation has been reported previously and conferred 
resistance to 5, 6-bridged quinolones, but not to other quinolones (42). Similarly, no cross-
resistance to ciprofloxacin was found with the E. coli REDX06276 serial passage mutant 
(Table S2). To understand the contribution of the GyrA Arg38Leu substitution to the 
increased resistance of E. coli REDX06276, 4 Redx compounds were tested against the 
mutant gyrase in the supercoiling assay (Table 1). Introduction of the Arg38Leu mutation 
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into the WT enzyme led to a modest increase in IC50 of 10 to 17 fold, except for 
REDX06213, which showed no significant change in activity. Whole-cell MIC testing 
revealed a loss in potency of 64-256 fold (Table S2), suggesting that additional off target 
mutations may be contributing to the resistance observed in this strain. Indeed, a mutation in 
the efflux repressor gene acrR, may have also contributed to increased resistance through 
attenuated suppression of acrB expression.   
 
Compounds in this series show a promising safety profile with HepG2 cytotox IC50 values of 
 µg/mL. Low hERG inhibition with the series has also been demonstrated, with IC50 
values >100 µM. During the optimisation of this series, efforts have been made to reduce 
hERG channel inhibition whilst retaining antibacterial potency. The addition of a fluorine 
atom in the southern group of REDX07623 appears to increase the hERG affinity in 
comparison to its matched pair, REX06276, with IC50 values of 8.2 and >33 µM, respectively. 
Introduction of more polar groups to reduce the logD of NBTI compounds has been shown to 
be associated with reduced hERG inhibition (22). REDX06181 displayed the lowest logD of 
the compounds tested and showed the most attenuated hERG inhibition with an IC50 >100 
µM. However, its antibacterial potency was reduced compared to other compounds with a 
higher logD, such as REDX07623. A negative correlation between whole-cell antibacterial 
potency and hERG inhibition has been reported for other NBTI type compounds (22). 
 
In summary, the NBTI series described here shows potent, balanced, dual-targeting 
inhibition of DNA gyrase and topoisomerase IV, with selectivity over human topoisomerase 
II. Data from DNA cleaved complex experiments indicates the series has a different 
mechanism-of-action to the fluoroquinolones. The low mutation rate of Gram-negative 
strains to the compounds combined with the balanced inhibitory enzyme activity suggests 
resistance could be slow to develop during therapeutic use. Antibacterial activity was 
demonstrated against a wide panel of susceptible and drug-resistant bacterial species 
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including the ESKAPE set of organisms, medically-important anaerobic species and other 
pathogens, including larger sets of MDR isolates thereof. Rapid, bactericidal activity was 
also demonstrated. These properties, in combination with the promising in vitro safety 
profile, warrant the further development of this NBTI series. 
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TABLE 1 Inhibition of the DNA supercoiling and cleaved complex formation activities of E. 
coli DNA gyrase (WT and Arg38Leu mutant), the decatenation activity of E. coli 
topoisomerase IV, and the decatenation activity of human topoisomerase II by ciprofloxacin 
and exemplar Redx NBTI compounds. 
 
Ciprofloxacin 
REDX 
05777 
REDX 
06181 
REDX 
06213 
REDX 
07623 
REDX 
07638 
E. coli DNA gyrase (WT) IC50 (µM) 0.77 0.29 1.47 1.66 0.21 0.23 
E. coli DNA gyrase (Arg38Leu mutant) IC50 (µM) 1.32 ND 21.8 1.83 3.57 2.31 
E. coli DNA gyrase cleavage complex (% 
cleaved at 100 µM)  
35.0 0 2.6 3.5 0 0 
E. coli topoisomerase IV IC50 (µM) 10.20 0.25 1.17 0.14 0.10 0.10 
Human topoisomerase II IC50 (µM) 500 >100 84 100 >100 100 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
TABLE 2 Bacterial susceptibility profile of NBTI compounds against reference bacterial 
strains and FQR mutants. 
Species and 
strain 
MIC (µg/mL) 
Ciprofloxacin 
REDX 
05777 
REDX 
06181 
REDX 
06213 
REDX 
06276 
REDX 
07623 
REDX 
07638 
Acinetobacter 
baumannii 
NCTC 13420 
64 2 16 0.12 0.25 0.25 0.25 
Clostridium 
difficile  
ATCC 700557 
16 n.d. n.d. 2 n.d. 2 n.d. 
Enterobacter 
cloacae 
NCTC 13406 
0.015 8 8 2 1 2 2 
Enterococcus 
faecalis 
ATCC 29212 
1 2 2 1 0.5 1 1 
Enterococcus 
faecium ATCC 
19434 
8 4 8 2 2 2 2 
Escherichia 
coli 
ATCC 25922 
0.03 0.5 1 0.12 0.25 0.5 0.5 
E. coli 
MG1655  
WT 
0.008 0.5 1 0.25 0.5 0.5 0.5 
27 
E. coli 
MG1655  
S83L 
0.12 0.5 0.5 0.25 0.25 0.25 0.25 
E. coli 
MG1655  
D87G 
0.06 1 0.5 0.5 1 1 1 
E. coli  
ECCPX1- 
SP25 
32 4 1 1 0.5 1 2 
Haemophilus 
influenzae 
ATCC 49247 
0.008 4 4 2 2 4 2 
Klebsiella 
pneumoniae 
ATCC 700603 
0.25 16 32 8 8 8 8 
Mycobacterium 
tuberculosis 
H37Rv 
2.2 1.3 n.d. n.d. n.d. n.d. n.d. 
Neisseria 
gonorrhoeae 
ATCC 49226 
0.004 4 16 2 1 2 2 
Pseudomonas 
aeruginosa 
ATCC 27853 
1 8 8 4 4 8 4 
Staphylococcus 
aureus 
ATCC 29213 
0.25 1 4 0.12 0.25 0.5 0.12 
28 
Streptococcus 
pneumoniae 
ATCC 49619 
0.5 2 4 0.5 0.25 0.5 0.25 
 
n.d., not determined 
 
TABLE 3 Susceptibility profile of a panel of biodefence pathogens to REDX07638 and the 
comparator antibiotic doxycycline. 
Species and strain MIC (µg/mL) 
Doxycycline REDX07638 
Bacillus anthracis Ames 0.03 0.5 
Burkholderia mallei China 7 0.12 8 
Burkholderia pseudomallei DD503 2 32 
Burkholderia pseudomallei K96243 2 32 
Burkholderia pseudomallei 1026b 1 16 
Francisella tularensis SCHU S4 0.5 4 
Yersinia pestis CO92 2 1 
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TABLE 4 MIC90 (µg/mL) of NBTI compounds and levofloxacin for a panel of recently isolated 
levofloxacin-resistant and multidrug-resistant clinical isolates. 
Species 
(number of isolates) 
MIC90 (range), µg/mL 
Levofloxacin REDX06213 REDX06276 REDX07623 
K. pneumoniae 
(42) 
16 (0.03->64) 32 (2->64) 16 (2->64) 32 (4->64) 
A. baumannii 
(43) 
16 (0.06->64) 8 (1-16) 8 (0.5-16) 4 (0.5-32) 
P. aeruginosa 
(42) 
64 (0.03->64) 32 (2->64) 32 (2-64) 32 (4->64) 
E. cloacae 
(41) 
32 (0.03->64) 32 (4->64) 32 (4->64) 32 (4->64) 
E. coli 
(43) 
16 (0.03->64) 4 (1->64) 4 (0.5->64) 8 (1->64) 
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TABLE 5 Bacterial susceptibility profile of NBTI compounds and comparator antibiotics 
against a panel of recent clinical isolates of 10 anaerobic bacterial species. 
Species  
(number of isolates) 
MIC90 (range), µg/mL 
Metronidazole Vancomycin Ciprofloxacin REDX06213 REDX07623 
Clostridium perfringens 
(11) 
1 (0.25-1) 0.5 (0.5) 0.5 (0.25-0.5) 2 (0.25-2) 2 (0.5-4) 
Finegoldia  
magna (12) 
0.5 (0.5-1) 0.5 (0.25-0.5) 32 (0.25-32) 16 (1->64) 32 (0.5->64) 
Parvimonas  
micra (12) 
1 (0.25-1) 1 (-4) 16 (0.5-16) 64 (2-64) 64 (0.5-64) 
Peptostreptococcus 
anaerobius (10) 
0.5 (0.25-0.5) 0.5 (0.25->64) 16 (0.5-16) 0.25 (0.12-8) 1 (0.12-8) 
Propionibacterium acnes 
(12) 
>32  (>32) 0.5 (0.25-16) 1 (0.25-2) 0.5 (0.12-0.5) 4 (0.12-4) 
Peptoniphilus  
harei (12) 
1 (0.25-1) 0.12 (0.12) 4 (1-16)  (0.12-0.25) 0.5 (0.12-0.25) 
Bacteroides 
fragilis (12) 
0.5 (0.25-0.5) 32 (16-32) 16 (2-32) 4 0.(25-64) 4 (0.5-64) 
Bacteroides 
thetaiotaomicron (11) 
1 (0.5-1) 64 (0.5-64) 64 (0.5-64) 16 (0.25-16) 8 (1-8) 
Prevotella 
bivia (10) 
2 (1-2) >64 (32->64) 32 (8-64) 8 (2-8) 8 (2-8) 
Prevotella 
melaninogenica (11) 
0.25 (0.06-0.5) >64 (8->64) 4 (0.5-8) 2 (0.12-4) 4 (0.12-4) 
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TABLE 6 In vitro safety profile of NBTI compounds and ciprofloxacin. 
 
REDX 
05777 
REDX 
06181 
REDX 
06213 
REDX 
06276 
REDX 
07623 
REDX 
07638 
HepG2  
IC50 (µg/mL) 
>64 >64 29.6 >64 >64 38 
hERG  
IC50 (µM) 
>33 >100 >33 >33 8.2 8.9 
logD 0.4 -0.64 0.94 0.71 1.26 1.39 
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FIGURE 1 Chemical structures of the compounds described in this study. 
  
FIGURE 2 Bactericidal activity of REDX06213 and REDX7623 at 4 × and 8 × MIC against A. 
baumannii NCTC 13420  
 
FIGURE 3 Isolation of drug-resistant mutants of E. coli ATCC 25922 by serial passage. 
Closed circles, REDX06276; open triangles, ciprofloxacin; open squares, delafloxacin. 
 
 
 
 
